CEACAM8 Antibody - #DF10151

FIGURE 2 Platelet‐neutrophil interaction triggers NET generation in glioma patients. (A) Control neutrophils were incubated with PLT‐rich plasma from glioma patients and healthy subjects and stained with MPO (red) and DAPI (blue). (B) Plasma from stage III/IV glioma patients activated neutrophils to release higher proportions of NETs than those from stage I/II glioma patients and healthy subjects. (C) Immunofluorescence images also showed PLTs (CD41, green) decorated on DNA traps (DAPI, blue) when neutrophils (CD66b, red) were incubated with plasma from glioblastoma (GBM; stage IV glioma) patients. (D) PLT‐neutrophil aggregates, defined as CD41+/CD66b+ cells, were investigated in samples from each group. (E) The rate of PLT‐neutrophil aggregates was highest in samples from GBM patients. (F) Control neutrophils were incubated with PLTs from glioma patients and healthy subjects and analyzed by immunofluorescence microscopy. PLTs from stage III/IV glioma patients, especially GBM patients, were potent activators of NET formation than those from stage I/II glioma patients and healthy subjects. (G, H) Anti‐P‐selectin and PSGL‐1 antibodies were used to inhibit the interaction between neutrophils and PLTs and the NET (propidium iodide, red) formation was markedly decreased. The scale bar in (A) and (G) is 20 μm and (C) is 80μm. The results are expressed as the mean±SD. *p<.05, **p<.01, ***p<.001, and ****p<.0001. DAPI, 4′,6‐diamidino‐2‐ phenylindole; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PLT, platelet